RodolfoEduardoBordoniMD

Oncology • Atlanta, GA

Physician

Join to view full profile

Are you Dr. Bordoni?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 35 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
1100 Johnson Ferry Rd
Ste 600
Atlanta, GA 30342
Phone+1 404-256-4777

Fax+1 404-256-5515
Is this information wrong?

Summary

Dr. Rodolfo Bordoni, MD is an oncologist in Atlanta, Georgia. He is currently licensed to practice medicine in Georgia and Texas. He is affiliated with Northside Hospital, WellStar Kennestone Hospital, and WellStar Cobb Hospital.

Education & Training

Emory University School of MedicineFellowship, Hematology and Medical Oncology, 1985 - 1988
Universidad Nacional de Rosario Faculty of MedicineClass of 1977

Certifications & Licensure

GA State Medical License 1988 - 2025
TX State Medical License 1991 - 1992

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013

Clinical Trials

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Start of enrollment: 2015 Oct 05
Terminated
Phase 1, Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC Start of enrollment: 2017 Jun 29
Terminated
Phase 2
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer Start of enrollment: 2019 Nov 05
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

2 citations
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.
Dipti Patel-Donnelly, Timothy Larson, Ralph Boccia, Vivian J M Cline, Adrija Mamidipalli, Jingmin Liu, Alev Akyol, Yasenchak, C. A., Jonathan W Friedberg, Rodolfo Bord...> ;Blood. 2024 Feb 29
3 citations
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.
Amer M Zeidan, Rachel J Cook, Rodolfo Bordoni, James R Berenson, William J Edenfield, Sanjay Mohan, Gongfu Zhou, Ekaterine Asatiani, Nithya Srinivas, Michael R Savona> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Jul 1
188 citations
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.
Makoto Nishio, Fabrice Barlesi, Howard Jack West, Simon Ball, Rodolfo Bordoni, Manuel Cobo, Pascale Dubray Longeras, Jerome H. Goldschmidt, Silvia Novello, Francisco O...> ;Journal of Thoracic Oncology. 2021 Apr 1
80 citations
Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study
J. von Pawel, Rodolfo Bordoni, Miyako Satouchi, Louis Fehrenbacher, M. Cobo, J-Y. Han, Toyoaki Hida, Denis Moro-Sibilot, Paul Conkling, David R. Gandara, Achim Rittmey...> ;European Journal of Cancer. 2019 Jan 1
49 citations
Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer.
Rodolfo Bordoni, Fortunato Ciardiello, Joachim von Pawel, Diego Cortinovis, Thomas Karagiannis, Marcus Ballinger, Alan Sandler, Wei Yu, Pei He, C. Matheny, Federico Fe...> ;Clinical Lung Cancer. 2018 May 31
46 citations
Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus.
Alexa B. Schrock, Dean Pavlick, Samuel J. Klempner, Jon Chung, Brady Forcier, Allison Welsh, Lauren Young, Bryan Leyland-Jones, Rodolfo Bordoni, Richard D. Carvajal, J...> ;Clinical Cancer Research. 2018 Apr 15
26 citations
Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing
Alexa B. Schrock, Garrett M. Frampton, Dana Herndon, Joel R. Greenbowe, Kai Wang, Doron Lipson, Roman Yelensky, Zachary R. Chalmers, Juliann Chmielecki, Julia A. Elvin...> ;Clinical Cancer Research. 2016 Mar 1
58 citations
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL
Jonathan W. Friedberg, Andres Forero-Torres, Rodolfo Bordoni, Vivian Jean M. Cline, Dipti Patel Donnelly, Patrick J. Flynn, Gregg Olsen, Robert T. Chen, Abraham P. Fon...> ;Blood. 2017 Dec 28
3 citations
Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients.
Ankit Madan, Benjamin S. Jones, Rodolfo Bordoni, Mansoor N. Saleh, Mary S. Jerome, Deborah Miley, Bradford E. Jackson, Francisco Robert> ;Cancer Chemotherapy and Pharmacology. 2016 Jul 14
15 citations
Identification of BRAF Kinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy.
Samuel J. Klempner, Rodolfo Bordoni, Kyle Gowen, Henry G. Kaplan, Philip J. Stephens, Sai-Hong Ignatius Ou, Siraj M. Ali> ;JAMA Oncology. 2016 Feb 1
95 citations
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older
Andres Forero-Torres, Beata Holkova, Jerome H. Goldschmidt, Robert T. Chen, Gregg Olsen, Ralph V. Boccia, Rodolfo Bordoni, Jonathan W. Friedberg, Jeff P. Sharman, Mari...> ;Blood. 2015 Dec 24
1 citations
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small ce...
Daniel Joseph Allendorf, Rodolfo Bordoni, Stefan C. Grant, Mansoor N. Saleh, Vishnu Reddy, Mary Jerome, Pamela M. Dixon, Deborah Miley, Karan P. Singh, Francisco Robert> ;Cancer Chemotherapy and Pharmacology. 2015 Sep 22
6 citations
Cushing's syndrome due to ectopic adrenocorticotrophic hormone production by olfactory neuroblastoma.
Nitin Mayur, Rodolfo E. Bordoni, Drew Locandro, Mark McLaughlin> ;Endocrine Practice. 2014 Mar 1
5 citations
Hematologic Outcomes of Myelodysplastic Syndromes Treatment With Hypomethylating Agents in Community Practice
Rodolfo E. Bordoni, Bruce A. Feinberg, James Gilmore, Sally Haislip, James H. Jackson, Eileen Farrelly, Edward Kim, Deborah Buchner> ;Clinical Lymphoma, Myeloma & Leukemia. 2011 Aug 1
10 citations
An uncommon case of de novo CD10+ CD5- mantle cell lymphoma mimics follicle center B cell lymphoma.
Mauricio Zapata, Steven D. Budnick, Rodolfo Bordoni, Shiyong Li> ;International Journal of Clinical and Experimental Pathology. 2010 Mar 20
33 citations
A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)
Mark A. Socinski, Mansoor N. Saleh, D. Trent, T. W. Dobbs, L. M. Zehngebot, M. A. Levine, Rodolfo Bordoni, P. J. Stella> ;Annals of Oncology. 2009 Jun 1
20 citations
Consensus conference: multimodality management of early- and intermediate-stage non-small cell lung cancer.
Rodolfo Bordoni> ;The Oncologist. 2008 Sep 1
4 citations
Purification and characterization of recombinant melanoma growth stimulating activity.
H G Thomas, Jin Hee Han, E. Balentien, Rik Derynck, R. Bordoni, Ann Richmond> ;Methods in Enzymology. 1991 Jan 1
272 citations
Molecular characterization and chromosomal mapping of melanoma growth stimulatory activity, a growth factor structurally related to beta-thromboglobulin.
Ann Richmond, E. Balentien, H. G. Thomas, G. Flaggs, David E. Barton, J. Spiess, R. Bordoni, U. Francke, Rik Derynck> ;The EMBO Journal. 1988 Jul 1
67 citations
Characterization of the role of melanoma growth stimulatory activity (MGSA) in the growth of normal melanocytes, nevocytes, and malignant melanocytes
R. Bordoni, R. Fine, Douglas R. Murray, Ann Richmond> ;Journal of Cellular Biochemistry. 1990 Dec 1
13 citations
Growth factor modulation of melanoma growth stimulatory activity mRNA expression in human malignant melanoma cells correlates with cell growth
R. Bordoni, G. Thomas, Ann Richmond> ;Journal of Cellular Biochemistry. 1989 Apr 1
Join now to see all

Hospital Affiliations

Northside HospitalAtlanta, Georgia
WellStar Kennestone HospitalMarietta, Georgia
Northside Hospital-CherokeeCanton, Georgia
Northside Hospital-ForsythCumming, Georgia
WellStar Cobb HospitalAustell, Georgia